Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company’s shares closed last Thursday at $76.61.
According to TipRanks.com, Syed is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.0% and a 46.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $77.19, which is a -6.0% downside from current levels. In a report issued on April 13, RBC Capital also maintained a Buy rating on the stock with a $85.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $85.98 and a one-year low of $60.89. Currently, Gilead Sciences has an average volume of 23.03M.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in February 2020, Kevin Lofton, a Director at GILD bought 21,720 shares for a total of $426,364.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Read More on GILD:
